

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-28 (Cancelled).

29. (Previously Presented) A method for treating cancer, the method comprising:

- (a) stimulating peripheral-blood mononuclear cells (PBMC) with immobilized anti-CD3 antibodies to produce primary stimulated PBMC;
 - (b) adding naïve PBMC to the primary stimulated PBMC;
 - (c) incubating the naïve PBMC added in step (b) in the presence of the primary stimulated PBMC produced in step (a) to stimulate the naïve PBMC by the primary stimulated PBMC, thereby obtaining PBMC that have been stimulated via cascade priming of steps (a) to (c) (CAPRI cells); and
 - (d) administering the CAPRI cells into a cancer patient,
- wherein the primary stimulation of step (a) and/or the stimulation of naïve PBMC of step (c) occurs in the presence of at least one cytokine selected from the group of interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon γ (IFN- γ).

30. (Previously Presented) The method of Claim 29, wherein the cancer is selected from the group consisting of melanoma, breast carcinoma, colorectal carcinoma, ovarian carcinoma, glioblastoma multiform, and bowenoid papilloma.

31. (Previously Presented) The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells intradermally, intravenously, and/or intramuscularly.

32. (Previously Presented) The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells in a dosage range from 0.5 to 30 million cells per injection into the cancer patient.

33. (Previously Presented) The method of Claim 29, wherein administering the CAPRI cells comprises:

administering CAPRI cells into a tumor of the cancer patient, wherein the diameter of the tumor is less than 0.5 cm.

34. (Previously Presented) The method of Claim 29, wherein the CAPRI cells are administered in conjunction with radiotherapy.

35. - 44. (Cancelled).